Aminopterin is a medicine that was once used to treat certain types of cancer. It works by interfering with folic acid, which is needed for cell growth. It is not used much anymore because it can cause birth defects.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Aminopterin is a chemotherapy drug of historical importance rather than a medicine people are prescribed today. In 1948 it became the first drug shown to put children with acute leukemia into remission, even if only for weeks. That result helped launch modern cancer chemotherapy. Within a few years it was replaced by methotrexate, a closely related drug whose effects doctors found more predictable. Aminopterin is not an FDA-approved or marketed medicine in the US. It was also used off-label for psoriasis and, in the 1950s, to end pregnancies, which is how its ability to cause birth defects became known. Since the 2000s, researchers have tested it again in small studies, mainly in children with acute lymphoblastic leukemia (ALL), a blood cancer, and in early studies for psoriasis. Anyone receiving it now would be doing so as part of a research study.
Cells need folate (the natural form of folic acid, a B vitamin) to build DNA when they divide. To use folate, cells rely on an enzyme called dihydrofolate reductase. Aminopterin closely resembles folate and blocks this enzyme, so dividing cells run short of the building blocks for new DNA. Fast-growing leukemia cells are especially affected, which is why the drug can shrink a cancer. But healthy cells that divide quickly, such as those in the bone marrow, the lining of the mouth and gut, and a developing embryo, are affected too. That shared vulnerability explains both its benefit and its main harms. Methotrexate works the same way; aminopterin is more potent, and laboratory work suggests leukemia cells take it up and retain it more consistently.
There is no standard dose for everyday use, because aminopterin is not a marketed medicine. In recent leukemia trials, it was taken by mouth once a week, split into two doses given 12 hours apart, with the amount calculated from body size. It was absorbed reliably when swallowed, one of the reasons researchers revisited it. In a research setting, the study team sets the dose, schedules blood tests and decides whether to add leucovorin, a form of folate given afterward to protect healthy cells. The schedule matters: taking it more often than prescribed can cause serious toxicity.
At higher doses, mouth sores and inflammation of the lining of the mouth and gut were the effects that most often limited the dose in trials. Nausea, vomiting and loss of appetite can also occur. Blood tests may show changes in liver function, usually without symptoms. The most serious risk is suppression of the bone marrow, which lowers white blood cells that fight infection and platelets that help blood clot. Fever, chills, unusual bruising or bleeding during treatment should be reported to the treating team right away. In trials, lowering the dose or adding leucovorin reduced mouth sores and other toxicity.
Aminopterin causes serious harm in pregnancy. Exposure in the first trimester can lead to miscarriage or a recognizable pattern of birth defects called fetal aminopterin syndrome, which includes abnormal skull and facial development, cleft palate and limb or skeletal differences, along with poor growth before birth. Anyone who could become pregnant would need reliable contraception during a study, and a possible pregnancy should be raised with the study team immediately. Other medicines that block folate can add to its effects on healthy cells. They include methotrexate and trimethoprim, an antibiotic paired with sulfamethoxazole in Bactrim, which is also used to prevent a type of pneumonia in people with weakened immune systems. These should not be combined outside a planned treatment. People in a study should tell the team about every medicine and supplement they take, including folic acid, which may change how the drug works.
For most people, aminopterin is a piece of medical history rather than a treatment option, and its legacy lives on in methotrexate, which remains a core part of leukemia treatment and is widely used for other conditions, including some inflammatory and skin diseases. The modern evidence is limited. In one small study of children whose leukemia had stopped responding to other treatment, about a quarter had a meaningful response. A follow-up study found side effects manageable when it replaced methotrexate in combination treatment, but no large trial has shown that it works better than methotrexate. Anyone in a trial can expect frequent blood counts and liver tests, with the dose adjusted to the results.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aminopterin, what you've noticed, or ask the community a question.